DAVENPORT & Co LLC Acquires 812 Shares of Zoetis Inc. (NYSE:ZTS)

DAVENPORT & Co LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,139 shares of the company’s stock after acquiring an additional 812 shares during the quarter. DAVENPORT & Co LLC’s holdings in Zoetis were worth $9,501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Fairfield Bush & CO. purchased a new position in Zoetis in the first quarter worth $134,000. Sequoia Financial Advisors LLC grew its holdings in shares of Zoetis by 5.3% in the first quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock worth $786,000 after purchasing an additional 211 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Zoetis by 3.9% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock valued at $9,727,000 after purchasing an additional 1,914 shares during the period. Covestor Ltd lifted its stake in Zoetis by 102.8% in the first quarter. Covestor Ltd now owns 724 shares of the company’s stock worth $137,000 after acquiring an additional 367 shares during the period. Finally, Merit Financial Group LLC increased its position in shares of Zoetis by 92.8% during the first quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock valued at $442,000 after buying an additional 1,127 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZTS has been the subject of several recent research reports. The Goldman Sachs Group raised their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Piper Sandler upped their price objective on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. BNP Paribas started coverage on shares of Zoetis in a report on Thursday, December 7th. They set an “outperform” rating and a $237.00 target price for the company. Jefferies Financial Group restated a “buy” rating and issued a $230.00 price target on shares of Zoetis in a research note on Tuesday, December 19th. Finally, Barclays boosted their target price on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $222.11.

Get Our Latest Analysis on ZTS

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.12% of the company’s stock.

Zoetis Stock Down 1.3 %

ZTS stock opened at $162.94 on Thursday. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $151.03 and a twelve month high of $201.92. The stock has a market cap of $74.52 billion, a P/E ratio of 32.14, a PEG ratio of 2.52 and a beta of 0.85. The business’s 50-day moving average price is $184.16 and its 200-day moving average price is $181.77.

Zoetis (NYSE:ZTSGet Free Report) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.